Data from the current retrospective study highlight that both tumor morphology (i.e., tumor burden) and tumor-specific biomarkers (i.e., serum AFP) could be important when assessing the prognosis of patients who undergo resection for HCC. Here, AFP is linked to hepatocellular carcinoma.